Molecular farming - The slope of enlightenment

被引:100
作者
Fischer, Rainer [1 ,2 ,3 ]
Buyel, Johannes F. [2 ,4 ]
机构
[1] IBRI, 1345 W 16th St,Suite 300, Indianapolis, IN 45202 USA
[2] Rhein Westfal TH Aachen, Inst Mol Biotechnol, Worringerweg 1, D-52074 Aachen, Germany
[3] Purdue Univ, Purdue Inst Inflammat Immunol & Infect Dis, 207 S Martin Jischke Dr, W Lafayette, IN 47907 USA
[4] Fraunhofer Inst Mol Biol & Appl Ecol IME, Forckenbeckstr 6, D-52074 Aachen, Germany
关键词
Molecular farming; Plant platforms; Industrial and pharmaceutical products; Development cycle; Regulatory; LARGE-SCALE PRODUCTION; RECOMBINANT PHARMACEUTICAL PROTEINS; MONOCLONAL-ANTIBODY; COMMERCIAL PRODUCTION; HIGH-LEVEL; TOBACCO; PLANTS; EXPRESSION; CELL; VACCINES;
D O I
10.1016/j.biotechadv.2020.107519
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Molecular farming can be defined as the use of plants to produce recombinant protein products. The technology is now > 30 years old. The early promise of molecular farming was based on three perceived advantages: the low costs of growing plants, the immense scalability of agricultural production, and the inherent safety of plants as hosts for the production of pharmaceuticals. This resulted in a glut of research publications in which diverse proteins were expressed in equally diverse plant-based systems, and numerous companies were founded hoping to commercialize the new technology. There was a moderate degree of success for companies producing nonpharmaceutical proteins, but in the pharmaceutical sector the anticipation raised by promising early research was soon met by the cold hard reality of industrial pragmatism. Plants did not have a track record of success in pharmaceutical protein manufacturing, lacked a regulatory framework, and did not perform as well as established industry platforms. Negative attitudes towards genetically modified plants added to the mix. By the early 2000s, major industry players started to lose interest and pharmaceutical molecular farming fell from a peak of expectation into a trough of disillusionment, just as predicted by the Gartner hype cycle. But many of the pioneers of molecular farming have refocused their activities and have worked to address the limitations that hampered the first generation of technologies. The field has now consolidated around a smaller number of better-characterized platforms and has started to develop standardized methods and best practices, mirroring the evolution of more mature industry sectors. Likewise, attention has turned from proof-of-principle studies to realistic techno-economic modeling to capture significant niche markets, replicating the success of the industrial molecular farming sector. Here we argue that these recent developments signify that pharmaceutical molecular farming is now climbing the slope of enlightenment and will soon emerge as a mature technology.
引用
收藏
页数:16
相关论文
共 112 条
  • [71] Chlamydomonas reinhardtii as a viable platform for the production of recombinant proteins: current status and perspectives
    Rosales-Mendoza, Sergio
    Teresita Paz-Maldonado, Luz Maria
    Elena Soria-Guerra, Ruth
    [J]. PLANT CELL REPORTS, 2012, 31 (03) : 479 - 494
  • [73] From gene to harvest: insights into upstream process development for the GMP production of a monoclonal antibody in transgenic tobacco plants
    Sack, Markus
    Rademacher, Thomas
    Spiegel, Holger
    Boes, Alexander
    Hellwig, Stephan
    Drossard, Juergen
    Stoger, Eva
    Fischer, Rainer
    [J]. PLANT BIOTECHNOLOGY JOURNAL, 2015, 13 (08) : 1094 - 1105
  • [74] Extremely High-Level and Rapid Transient Protein Production in Plants without the Use of Viral Replication
    Sainsbury, Frank
    Lomonossoff, George P.
    [J]. PLANT PHYSIOLOGY, 2008, 148 (03) : 1212 - 1218
  • [75] Rapid Transient Production in Plants by Replicating and Non-Replicating Vectors Yields High Quality Functional Anti-HIV Antibody
    Sainsbury, Frank
    Sack, Markus
    Stadlmann, Johannes
    Quendler, Heribert
    Fischer, Rainer
    Lomonossoff, George P.
    [J]. PLOS ONE, 2010, 5 (11):
  • [76] Putting the Spotlight Back on Plant Suspension Cultures
    Santos, Rita B.
    Abranches, Rita
    Fischer, Rainer
    Sack, Markus
    Holland, Tanja
    [J]. FRONTIERS IN PLANT SCIENCE, 2016, 7
  • [77] Schillberg S., 2017, APPL BIOENGINEERING, P261
  • [78] Critical Analysis of the Commercial Potential of Plants for the Production of Recombinant Proteins
    Schillberg, Stefan
    Raven, Nicole
    Spiegel, Holger
    Rasche, Stefan
    Buntru, Matthias
    [J]. FRONTIERS IN PLANT SCIENCE, 2019, 10
  • [79] Molecular Farming of Pharmaceutical Proteins Using Plant Suspension Cell and Tissue Cultures
    Schillberg, Stefan
    Raven, Nicole
    Fischer, Rainer
    Twyman, Richard M.
    Schiermeyer, Andreas
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (31) : 5531 - 5542
  • [80] Field-grown tobacco plants maintain robust growth while accumulating large quantities of a bacterial cellulase in chloroplasts
    Schmidt, Jennifer A.
    McGrath, Justin M.
    Hanson, Maureen R.
    Long, Stephen P.
    Ahner, Beth A.
    [J]. NATURE PLANTS, 2019, 5 (07) : 715 - 721